All In Biotech

Drug Trial Radar · NCT03896737

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

A Multicenter, Open Label, Randomized Phase II Study Comparing Daratumumab Combined With Bortezomib-Cyclophosphamide-dexamethasone (Dara-VCd) Versus the Association of Bortezomib-Thalidomide-dexamethasone (VTd) as Pre Transplant Induction and Post Transplant Consolidation, Both Followed by a Maintenance Phase With Ixazomib Alone or in Combination With Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible for Autologous Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

401

Actual

Start

Apr 16, 2019

Primary completion

Jun 30, 2026

Study completion Sep 15, 2027

Sponsor

Lead sponsor
European Myeloma Network B.V.Research network
Sponsor type
Research network
Collaborators
EMN Trial Office S.r.l. Impresa Sociale
First posted
Apr 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of bortezomib, thalidomide and dexamethasone (VTd) as pre transplant induction and post transplant consolidation, followed by maintenance with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) patients eligible for autologous stem cell transplantation. Patients enrolled in the Dara-VCd arm will receive: 4 cycles of daratumumab-bortezomib-cyclophosphamide-dexamethasone induction, followed by transplantation and 2 cycles of daratumumab-bortezomib-cyclophosphamide-dexamethasone consolidation. The choice of cyclophosphamide in combination with bortezomib and dexamethasone is suggested by the better safety profile of cyclophosphamide, in comparison with thalidomide and the efficacy of the alkylator agent, when combined with bortezomib. Once-weekly bortezomib seems to be equally effective and better tolerated than the standard twice weekly schedule. The outcomes and response rate did not appear to be affected by the bortezomib dosing schedule. Patients enrolled in the VTd arm will receive: 4 cycles of bortezomib-thalidomide-dexamethasone induction, followed by autologous transplantation and 2 cycles of bortezomib-thalidomide dexamethasone as consolidation. The VTd drug association is the current standard first line induction therapy for multiple myeloma patients who are eligible to stem cell transplantation. At the end of consolidation phase patients with at least a partial response (≥ PR) will be rerandomized (assigned by chance) to one of 2 treatment groups to receive maintenance treatment with ixazomib alone or in combination with daratumumab. Patients will receive treatment until any sign of progression or intolerance, up to 24 months.

Conditions

  • Multiple Myeloma

Interventions

  • Daratumumab plus Velcade Cyclophosphamide DexamethasoneDrug

    To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.

  • Velcade Thalidomide DexamethasoneDrug

    To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: 5 years
  2. MRD negativityTime frame: 5 years

Locations

24 sites in 3 countries. Site status is shown where the registry gives one.

  • Hradec Kralove-University Hospital Hradec Kralove

    Hradec Králové, Czechia

  • University Hospital Olomouc

    Olomouc, Czechia

  • University Hospital Ostrava

    Ostrava, Czechia

  • University Hospital Ostrava

    Ostrava, Czechia

  • University Hospital Plzen

    Pilsen, Czechia

  • General University Hospital (VFN)-Internal Medicine, Hematology Clinic

    Prague, Czechia

  • General Hospital of Athens "Alexandra"

    Athens, Greece

  • General Hospital of Athens 'Evangelismos

    Athens, Greece

  • University General Hospital of Patras

    Pátrai, Greece

  • A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona

    Ancona, Italy

  • A.O. Papa Giovanni XXIII

    Bergamo, Italy

  • Policlinico S. Orsola

    Bologna, Italy

  • A.O. Spedali Civili di brescia

    Brescia, Italy

  • A.O.U. Policlinico Vittorio Emanuele di Catania

    Catania, Italy

  • A.O.U. Policlinico San Martino

    Genova, Italy

  • Ospedale Niguarda

    Milan, Italy

  • A.O.U. Maggiore della Carità di Novara

    Novara, Italy

  • Dipartimento Medicina Clinica e Sperimentale - AO di Padova

    Padova, Italy

  • Policlinico S. Matteo Fondazione IRCCS

    Pavia, Italy

  • A.O. di Perugia-Ospedale S. Maria della Misericordia

    Perugia, Italy

  • Arcispedale S. Maria Nuova

    Reggio Emilia, Italy

  • I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Italy

  • Az. Osp. S. Maria

    Terni, Italy

  • AOU Città della Salute e della Scienza di Torino

    Torino, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.